Malignant hyperthermia during epidural anesthesia

Journal of Clinical Anesthesia

Volumn 8, Issue 2, 1996, Pages 157-160

  Motegi, Y ^a   Shirai, M ^b   Arai, M ^b   Kato, S ^b   Kawana, Y ^b   Goto, F ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

calcium induced calcium release; Complications; dantrolene; local anesthetic; malignant hyperthermia; pharmacology

Indexed keywords

BICARBONATE; DANTROLENE; PHENYTOIN;

ADOLESCENT; ANESTHESIA COMPLICATION; ARTICLE; CALCIUM TRANSPORT; CASE REPORT; CONTRACTURE; DIAGNOSTIC VALUE; EPIDURAL ANESTHESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL;

EID: 0029924142     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/0952-8180(95)00204-9     Document Type: Article

References (18)

1. Kawana Y, Iino M, Horiuti K, Matsumura N, Ohta T, Matsui K, Endo M: Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed Res 1992;13:287-97.
2. Sharrock NE, Savarese JJ: Anesthesia for orthopaedic surgery. In: Miller RD (ed): Anesthesia. New York: Churchill-Livingstone, 1981:1962-4.
3. Pollock N, Hodges M, Sendall J: Prolonged malignant hyperthermia in the absence of triggering agents. Anesth Intensive Care 1992; 20:520-3.
4. Ruhland G, Hinkle AJ: Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia. Anesthesiology 1984;60:159-60.
5. Flewellen EH, Nelson TE: Prophylactic and therapeutic doses of dantrolene for malignant hyperthermia [Letter]. Anesthesiology 1984;61:477.
6. Hara Y, Kato A, Horikawa H, Kato Y, Ichiyanagi K: Postoperative respiratory depression thought to be due to oral dantrolene pretreatment in a malignant hyperthermia-susceptible patient. Jpn J Anesthesiol 1988;37:483-7.
7. Watson CB, Reierson N, Norfleet EA: Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology 1986;65:312-4.
8. Flewellen EH, Nelson TE, Bee DE: Effect of dantrolene on neuromuscular block by d-tubocurarine and subsequent antagonism by neostigmine in the rabbit. Anesthesiology 1980;52:126-30.
9. Pandit SK, Kothary SP, Cohen PJ: Orally administered dantrolene for prophylaxis of malignant hyperthermia. Anesthesiology 1979; 50:156-8.
10. Ohnishi ST: Calcium-induced calcium release from fragmented sarcoplasmic reticulum. J Biochem 1979;86:1147-50.
11. Strobel GE, Bianchi CP: An in-vitro model of anesthetic hypertonic hyperpyrexia, halothane - caffeine-induced muscle contractures: prevention of contracture by procainamide. Anesthesiology 1971;35:465-73.
12. Harrison GG, Morrell DF: Response of mhs swine to i.v. infusion of lignocaine and bupivacaine. Br J Anaesth 1980;52:385-7.
13. Berkowitz A, Rosenberg H: Femoral block with mepivacaine for muscle biopsy in malignant hyperthermia patients. Anesthesiology 1985;62:651-2.
14. Gronert GA, Thompson RL, Onofrio BM: Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth Analg 1980;59:377-8.
15. Ueda O, Kim S, Ishizaki A, Matsukawa M, Uchiyama M, Yamamoto T: A case of non-rigid type malignant hyperthermia in which release of tourniquets might be considered one of the important factors to induce cardiac arrest. Masuitososei 1989;25:103-5.
16. Kalow W, Britt BA, Terreau ME, Haist C: Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970;2(679):895-8.
17. 2+ release in skinned fibers from skeletal muscle. Methods Enzymol 1988;157:12-26.
18. MacLennan DH, Phillips MS: Malignant hyperthermia. Science 1992;256:789-94.